|
Join Med Ad News editors Steven
Niles and Joshua Slatko as The Med Ad News Show
continues its five-part Podcast series featuring
John Kamp, executive director of the Coalition for
Healthcare Communication.
Just released:
EPISODE 3: Don't
Forget FDAAA
Sponsored by CommonHealth, a WPP
company
John Kamp
discusses what is yet to come from the Food and Drug
Administration Amendments Act of 2007, including the
growing importance of Risk Evaluation and Mitigation
Strategies (REMS). In addition, Mr. Kamp details a
host of hidden threats to healthcare communication
coming from a variety of powerful institutions that
are trying to throw pharmaceutical marketers out of
organized medicine.
Click
here to download Episode 3
Also
Available:
EPISODE 1:
Tax Terror
Industry narrowly avoided an elimination of
the marketing expense tax exemption in the healthcare
reform bill. However, it's a popular idea in
Washington that could rear its head again with
potentially devastating effect for the healthcare
communications industry. John Kamp explains why the
threat continues to keep him up at
night.
Download
now
EPISODE 2:
The New FDA
A
new FDA is in charge under Commissioner Margaret
Hamburg and Deputy Commissioner Joshua Sharfstein.
John Kamp discusses why he has confidence in the new
team and what a strong FDA will mean for the
healthcare industry.
Download
now
These
upcoming episodes of The Med Ad News Show
will be released separately every two
weeks:
EPISODE 4:
Approach with Caution
Following FDA's hearing
on the pharmaceutical industry's use of social media,
marketers are moving forward cautiously. John Kamp
talks about why legal departments will continue to
voice strong resistance to going too far, while he
also acknowledges the great opportunity social media
holds in improving the industry's relationship and
reputation with consumers.
EPISODE 5:
The Silver Lining
A silver lining may exist for
the healthcare communications industry. John Kamp
discusses why communications companies could see an
upswing in business as a number of factors take shape.
A competent, confident FDA has the potential to open a
wider approval window, bringing many new products to
market. Healthcare reform has the potential to bring
in many new patients demanding information about
available medicines. And agreement between the
pharmaceutical industry and government around the
importance of patient adherence will expand
opportunities for developing appropriate
messaging.
|
